Patient Disposition and Baseline Characteristics
ONCOLOGY
From September 5, 2019, to the data cut-off date (April 3, 2021), a total of 25 Japanese patients were enrolled and treated: 6 patients in the E7389-LF 1.7 mg/mgBaseline patient characteristicsAbbreviations: BSA, body surface area; E7389-LF, eribulin liposomal formulation; ECOG PS, Eastern Cooperative Oncology Group performance status.

